Century Therapeutics, Inc. (NASDAQ:IPSC) Stock Holdings Increased by State Street Corp

State Street Corp raised its holdings in shares of Century Therapeutics, Inc. (NASDAQ:IPSC) by 7.4% in the third quarter, HoldingsChannel reports. The institutional investor owned 836,914 shares of the company’s stock after purchasing an additional 57,323 shares during the quarter. State Street Corp’s holdings in Century Therapeutics were worth $1,431,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in IPSC. Rhumbline Advisers lifted its position in shares of Century Therapeutics by 56.0% during the 2nd quarter. Rhumbline Advisers now owns 52,466 shares of the company’s stock valued at $134,000 after acquiring an additional 18,828 shares during the last quarter. SG Americas Securities LLC purchased a new stake in shares of Century Therapeutics during the third quarter valued at $27,000. Dimensional Fund Advisors LP boosted its position in shares of Century Therapeutics by 141.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 75,315 shares of the company’s stock valued at $192,000 after purchasing an additional 44,155 shares during the period. Bank of New York Mellon Corp boosted its position in shares of Century Therapeutics by 110.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 149,000 shares of the company’s stock valued at $380,000 after purchasing an additional 78,088 shares during the period. Finally, Renaissance Technologies LLC increased its stake in Century Therapeutics by 6.1% in the 2nd quarter. Renaissance Technologies LLC now owns 165,500 shares of the company’s stock worth $422,000 after purchasing an additional 9,500 shares in the last quarter. Institutional investors and hedge funds own 50.20% of the company’s stock.

Century Therapeutics Stock Performance

IPSC stock opened at $1.04 on Friday. The firm has a 50 day simple moving average of $1.30 and a 200 day simple moving average of $1.73. Century Therapeutics, Inc. has a 52 week low of $0.95 and a 52 week high of $5.51. The stock has a market cap of $88.43 million, a P/E ratio of -0.56 and a beta of 1.65.

Century Therapeutics (NASDAQ:IPSC) last issued its earnings results on Tuesday, November 5th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.08. Century Therapeutics had a negative net margin of 4,837.73% and a negative return on equity of 61.66%. The company had revenue of $0.79 million during the quarter, compared to analyst estimates of $0.47 million. During the same quarter last year, the business posted ($0.55) EPS. Sell-side analysts predict that Century Therapeutics, Inc. will post -1.63 EPS for the current year.

Analyst Ratings Changes

IPSC has been the subject of several recent analyst reports. Chardan Capital decreased their target price on shares of Century Therapeutics from $17.00 to $11.00 and set a “buy” rating for the company in a report on Thursday, November 7th. HC Wainwright decreased their price objective on shares of Century Therapeutics from $9.00 to $5.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. Finally, Piper Sandler cut their target price on shares of Century Therapeutics from $12.00 to $4.00 and set an “overweight” rating on the stock in a research note on Monday. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Century Therapeutics presently has an average rating of “Buy” and an average target price of $10.00.

About Century Therapeutics

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.